Slovakia's National Reference Centre for Prion Diseases reports that the cerebrospinal fluid seeding assay RT-QuIC was positive in 75 of 77 consecutive symptomatic patients with genetically confirmed E200K genetic Creutzfeldt-Jakob disease, a sensitivity of 97.4 per cent. The study, by Zakova and colleagues at Slovak Medical University in Bratislava, was published in Frontiers in Neuroscience on 5 August 2026 and covers samples referred to the national laboratory between January 2020 and December 2024. Total tau, measured by ELISA, was raised in 64 of 77 patients (83.1 per cent), and 14-3-3 protein, detected by Western blot, in 42 of 77 (54.5 per cent).
The genotype pattern is the part clinicians are likely to note. All patients carried the E200K variant in PRNP, but they differed at codon 129, the common methionine/valine position that shapes prion disease presentation. RT-QuIC was positive in all 30 methionine/valine heterozygotes and in 45 of 47 methionine homozygotes, a difference the authors report as not statistically significant (p = 0.518). Total tau and 14-3-3, by contrast, were significantly more often positive in methionine homozygotes than in heterozygotes (both p < 0.0001). The authors describe RT-QuIC as the primary CSF assay in suspected E200K disease, with the conventional markers as complementary.
Slovakia is an unusual place to gather such a dataset. Where genetic forms account for roughly 10 to 15 per cent of human prion disease worldwide, work from the same Bratislava department published in Pathogens in April 2021 put the genetic share of confirmed Slovak cases at about 65 to 75 per cent, with a focal accumulation in the Orava region, and found four E200K carriers among 1,000 live-born children screened. That concentration is why a national laboratory can assemble 77 genetically confirmed cases in five years, a number that would take most countries decades.
The authors state the study's main limitation themselves: there was no comparison group of patients with non-prion neurological disorders or of healthy individuals, so specificity, predictive values and overall diagnostic accuracy could not be calculated. Sensitivity alone does not tell a clinician how often a test is positive in people who do not have the disease. RT-QuIC was introduced at the centre in 2023 and run prospectively after that, with earlier archived frozen samples tested retrospectively. Every patient studied was already symptomatic, so the figures say nothing about what these markers do in carriers who are still well. That distinction matters for the treatment pipeline: the first-in-human trial of the PrP-lowering antisense drug ION717, PrProfile, was designed for people with symptomatic prion disease, and prevention trials in pre-symptomatic PRNP carriers remain a stated goal rather than an open door.